OctoPlus and InnoCore to partner on a novel drug delivery platform for peptides and small molecules

22-Oct-2004

Leiden / Groningen. OctoPlus, a drug delivery and development company and InnoCore Technologies BV, a supplier of biodegradable polymeric drug delivery systems, announced today that they have entered into a collaboration to develop and market a novel injectable drug delivery platform. This platform is based on SynBiosysTM, a biodegradable polymeric system that enables development of controlled release formulations of peptides and small molecules. It complements OctoPlus' existing drug delivery platforms PolyActiveTM and OctoDEXTM. With these three platforms, OctoPlus is able to develop tailor-made controlled release formulations for all classes of injectable drug compounds.

SynBiosysTM is a patent-pending biodegradable multi-block copolymer system that is fully based on well-known and regulatory approved building blocks, such as lactide, glycolide, caprolactone and PEG. Its biodegradability, biocompatibility and easily programmable release characteristics make it an excellent platform for the controlled release of peptides and small molecules. In initial studies, it was shown to be feasible to develop a 6-months release formulation of a peptide based on the SynBiosys* polymer that shows true zero-order kinetics without initial burst release. It has further been demonstrated that the polymers can be made into various product configurations, such as coatings, membranes, microspheres and gels. SynBiosysTM is currently under pre-clinical evaluation by InnoCore Technologies BV for use as a biodegradable drug eluting coronary stent coating and drug-eluting implant.

"We are very delighted with this collaboration with OctoPlus, a player with a proven track record in the field of pharmaceutical formulation development and advanced drug delivery systems. It will definitely give a boost to the further development of SynBiosysTM injectable drug delivery systems and maximize its market potential within the pharmaceutical field", said Dr. Theo Flipsen, CEO of InnoCore Technologies BV.

"The SynBiosysTM system clearly complements our existing polymer platforms PolyActiveTM and OctoDEX TM " stated Dr. Joost J.M. Holthuis, President and CEO of OctoPlus. "What makes us unique with this agreement is that we can offer controlled release platforms for almost any injectable drug compound. It further strengthens our position as the partner of choice for the development of parenteral controlled release formulations."

https://www.bionity.com/en/news/40416/octoplus-and-innocore-to-partner-on-a-novel-drug-delivery-platform-for-peptides-and-small-molecules.html